Cancer-on-a-chip systems at the frontier of nanomedicine
Cancer-on-a-chip systems at the frontier of nanomedicine
复制标题
纳米医学前沿的芯片癌症系统
DOI：
10.1016/j.drudis.2017.03.011
复制
发表时间：
2017
影响因子：
7.4
通讯作者：
Zhang Weijia
中科院分区：
文献类型：
--
作者：
Zhang Yu Shrike;Zhang Yi-Nan;Zhang Weijia
纳米医学通过增强给药机制促进药物疗效。目前的细胞培养和临床前模型对纳米药物的转化是缓慢的。器官芯片平台有可能更好地复制人体系统的生物学和生理学。芯片上的癌症平台有潜力作为有效评估纳米药物的替代方案。纳米医学通过增强给药机制，为促进药物疗效提供了独特的机会。然而，与在实验室环境中进行的大量研究相比，其转化为临床的速度相对较慢。鉴于传统细胞培养模型和临床前动物模型的局限性，我们讨论了最近开发的癌症芯片平台的潜在效用，该平台最大限度地复制了人类肿瘤微环境的病理生理，作为有效评估纳米药物的替代方案。我们首先简要讨论了纳米医学，然后绘制了器官芯片平台发展的历史，以及它们作为模拟不同癌症以评估纳米药物功效的工具的最新演变，最后展望了该领域的未来前景。
HighlightsNanomedicine promotes drug efficacy through enhanced delivery mechanisms.The translation of nanomedicine is slow with current cell culture and preclinical models.Organ-on-a-chip platforms potentially better replicate the biology and physiology of the human system.Cancer-on-a-chip platforms have potentials to use as alternatives for effective evaluation of nanomedicine.Nanomedicine provides a unique opportunity for promoting drug efficacy through enhanced delivery mechanisms. However, its translation into the clinics has been relatively slow compared with the large amount of research occurring in laboratory settings. Given the limitations of conventional cell culture models and preclinical animal models, we discuss the potential utility of recently developed cancer-on-a-chip platforms, which maximally replicate the pathophysiology of the human tumor microenvironments, as alternatives for effective evaluation of nanomedicine. We begin with a brief discussion of nanomedicine, then chart the history of organ-on-a-chip platform development and their recent evolution as tools for modeling different cancers for assessing nanomedicine efficacy, concluding with future perspectives for the field.